Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company focused on developing drug-Fc conjugate therapeutics through its Cloudbreak庐 platform, has announced new equity grants to two employees. The Compensation Committee approved non-qualified stock options and restricted stock units (RSUs) totaling 12,100 shares of common stock under the company's 2020 Inducement Incentive Plan.
The stock options were granted at an exercise price of $48.71 per share, matching Cidara's closing price on June 30, 2025. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in four equal annual installments on specified quarterly vesting dates.
Cidara Therapeutics (Nasdaq: CDTX), un'azienda biotecnologica specializzata nello sviluppo di terapie coniugate farmaco-Fc tramite la sua piattaforma Cloudbreak庐, ha annunciato nuove assegnazioni di azioni a due dipendenti. Il Comitato per la Retribuzione ha approvato opzioni azionarie non qualificate e unit脿 azionarie vincolate (RSU) per un totale di 12.100 azioni ordinarie, nell'ambito del Piano Incentivi 2020 dell'azienda.
Le opzioni azionarie sono state concesse a un prezzo di esercizio di 48,71 $ per azione, corrispondente al prezzo di chiusura di Cidara del 30 giugno 2025. Le opzioni matureranno in quattro anni, con il 25% che maturer脿 dopo un anno e il resto che maturer脿 mensilmente nei successivi 36 mesi. Le RSU matureranno in quattro rate annuali uguali, secondo date di maturazione trimestrali specificate.
Cidara Therapeutics (Nasdaq: CDTX), una empresa biotecnol贸gica centrada en el desarrollo de terapias conjugadas f谩rmaco-Fc mediante su plataforma Cloudbreak庐, ha anunciado nuevas concesiones de acciones a dos empleados. El Comit茅 de Compensaci贸n aprob贸 opciones sobre acciones no calificadas y unidades restringidas de acciones (RSU) que suman 12,100 acciones ordinarias bajo el Plan de Incentivos de Inducci贸n 2020 de la compa帽铆a.
Las opciones sobre acciones se otorgaron a un precio de ejercicio de $48.71 por acci贸n, igualando el precio de cierre de Cidara el 30 de junio de 2025. Las opciones se consolidar谩n durante cuatro a帽os, con un 25% consolidado despu茅s de un a帽o y el resto consolid谩ndose mensualmente durante los siguientes 36 meses. Las RSU se consolidar谩n en cuatro cuotas anuales iguales en fechas trimestrales espec铆ficas.
Cidara Therapeutics (雮橃姢雼�: CDTX)電� Cloudbreak庐 頂岆灚韽检潉 韱淀暣 鞎诫-Fc 鞝戫暕 旃橂鞝滊ゼ 臧滊皽頃橂姅 氚旍澊鞓ろ厡韥� 旮办梾鞙茧, 霊� 歆侅洂鞐愱矊 靸堧鞖� 欤检嫕 氤挫儊鞚� 氚滍憸頄堨姷雼堧嫟. 氤挫儊 鞙勳洂須岆姅 須岇偓鞚� 2020雲� 鞙犽弰 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 齑� 12,100欤�鞚� 氤错喌欤检棎 雽�頃� 牍勳瀽瓴� 欤检嫕 鞓奠厴瓿� 鞝滍暅 欤检嫕 雼渼(RSU)毳� 鞀轨澑頄堨姷雼堧嫟.
欤检嫕 鞓奠厴鞚� 2025雲� 6鞗� 30鞚� Cidara 膦呹皜鞚� $48.71鞐� 頄夓偓臧�瓴╈溂搿� 攵�鞐悩鞐堨姷雼堧嫟. 鞓奠厴鞚� 4雲勳棎 瓯胳硱 氩犾姢韺呺悩氅�, 1雲� 頉� 25%臧� 氩犾姢韺呺悩瓿� 雮橂ǜ歆�電� 36臧滌洈 霃欖晥 毵れ洈 氩犾姢韺呺惄雼堧嫟. RSU電� 歆�鞝曤悳 攵勱赴氤� 氩犾姢韺� 雮犾鞐� 霐半澕 4雲� 霃欖晥 毵る厔 霃欖澕頃� 4須� 攵勴暊搿� 氩犾姢韺呺惄雼堧嫟.
Cidara Therapeutics (Nasdaq : CDTX), une soci茅t茅 de biotechnologie sp茅cialis茅e dans le d茅veloppement de th茅rapeutiques conjugu茅es m茅dicament-Fc via sa plateforme Cloudbreak庐, a annonc茅 de nouvelles attributions d鈥檃ctions 脿 deux employ茅s. Le comit茅 de r茅mun茅ration a approuv茅 des options d鈥檃chat d鈥檃ctions non qualifi茅es et des unit茅s d鈥檃ctions restreintes (RSU) totalisant 12 100 actions ordinaires dans le cadre du Plan d鈥橧ncitation 2020 de la soci茅t茅.
Les options d鈥檃chat d鈥檃ctions ont 茅t茅 attribu茅es 脿 un prix d鈥檈xercice de 48,71 $ par action, correspondant au cours de cl么ture de Cidara au 30 juin 2025. Les options seront acquises sur une p茅riode de quatre ans, avec 25 % acquis apr猫s un an et le reste acquis mensuellement sur 36 mois. Les RSU seront acquises en quatre versements annuels 茅gaux aux dates d鈥檃cquisition trimestrielles sp茅cifi茅es.
Cidara Therapeutics (Nasdaq: CDTX), ein Biotechnologieunternehmen, das sich auf die Entwicklung von Wirkstoff-Fc-Konjugat-Therapeutika 眉ber seine Cloudbreak庐-Plattform spezialisiert hat, hat neue Aktienzuteilungen an zwei Mitarbeiter bekannt gegeben. Das Verg眉tungskomitee genehmigte nicht qualifizierte Aktienoptionen und Restricted Stock Units (RSUs) im Gesamtumfang von 12.100 Aktien des Stammkapitals im Rahmen des Inducement Incentive Plans 2020 des Unternehmens.
Die Aktienoptionen wurden zu einem Aus眉bungspreis von 48,71 $ pro Aktie gew盲hrt, entsprechend dem Schlusskurs von Cidara am 30. Juni 2025. Die Optionen werden 眉ber vier Jahre vesten, wobei 25 % nach einem Jahr vesten und der Rest monatlich 眉ber 36 Monate verteilt vestet. Die RSUs werden in vier gleichen j盲hrlichen Raten an festgelegten viertelj盲hrlichen Vesting-Terminen vesten.
- None.
- None.
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak庐聽platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted non-qualified stock option awards and restricted stock units (RSUs) for an aggregate of 12,100 shares of its common stock to two new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of June 30, 2025. The stock option has an exercise price of
The foregoing equity awards were granted as inducements material to the employees entering into employment with Cidara, in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Cidara, or following a bona fide period of non-employment, as an inducement material to such individual鈥檚 entering into employment with Cidara, pursuant to Nasdaq Listing Rule 5635(c)(4).
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak庐 platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara鈥檚 lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of enrollment of its Phase 2b NAVIGATE trial in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received investigational new drug application clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit .
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
[email protected]
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
(628) 234-3889
[email protected]
FAQ
What equity grants did Cidara Therapeutics (CDTX) announce on July 1, 2025?
What is the vesting schedule for Cidara's (CDTX) newly granted stock options?
How do the RSUs vest in Cidara's (CDTX) new employee equity grants?
Why did Cidara Therapeutics (CDTX) issue these equity grants?
